Diabetic wounds and pressure ulcers affect 26 million patients annually[1]. Limited treatment options make diabetic pressure ulcers difficult to heal leading to sepsis, amputations, and social dysfunction[2,3]. Angiogenesis is critical for wound healing, as cells proliferate and migrate to repair tissue. Oxidative damage hinders this process, delaying tissue repair and regeneration in diabetic patients [4,5].
Antioxidants, such as hydrogen sulfide donors, withaferin-A, and epigallocatechin gallate(EGCG), show promise in enhancing angiogenesis and mitigating oxidative damage and inflammation. Withaferin-A reduces oxidative stress and inflammation, supporting vascular health. EGCG protects endothelial cells, reduces oxidative stress, and improves endothelial function-crucial in diabetic wounds. Its anti-inflammatory effects further aid vascular health and wound healing. ADT-OH, a hydrogen sulphide-donor, promotes vasodilation, reduces oxidative stress, and supports re-epithelialisation and collagen deposition, essential for wound repair[6,7].
However, rapid release rates and instability limit antioxidant delivery. To address this, we aim to develop novel dermal formulations loaded with antioxidants and evaluate their potential using a 3D-diabetic wound model. This approach could offer an effective therapeutic strategy to enhance wound healing and reduce complications in diabetic patients.
Aim: Develop and characterise biocompatible dermal gel formulations loaded with antioxidants to promote angiogenesis and re-epithelialisation in a 3D-diabetic wound model.
- Objective 1: Synthesis and characterisation of gels: Antioxidant-loaded gels will be developed and assessed using texture analysis and differential scanning calorimetry.
- Objective 2: Diabetic skin model: Co-culture of human umbilical vein endothelial cells and dermal fibroblasts will be established with keratinocytes seeded on top. Hyperglycaemic conditions will mimic diabetic inflammatory environment. Inflammatory markers (e.g., IL-6, ROS), cell viability, and morphology will confirm model accuracy.
- Objective 3: Formulation efficacy: Compound release will be assessed using HPLC-UV. Safety will be evaluated with Cell Titer blue assay, and wound healing potential tested by measuring wound closure rates and analysing inflammatory and oxidative stress markers.
References:
-
Yazdanpanah, L., et al. (2018). International Journal of Endocrinology, 2018, 7631659.
Sen, C. K., et al. (2009). [Journal title not provided], 17(6), 763–771.
-
Wu, L., et al. (2015). Cochrane Database of Systematic Reviews, (7).
-
Gallagher, K. A., et al. (2007). [Journal title not provided], 117(5), 1249–1259.
-
Frank, S., et al. (1995). [Journal title not provided], 270(21), 12607–12613.
-
Xu, M., et al. (2021). Journal of Advanced Research, 27, 11–17.
-
Zhao, X., et al. (2020). Acta Biomaterialia, 104, 85–94.